The Alexandra Hopsital
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Contact, First
PARTNER, NCT03150576: Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Recruiting
2/3
780
Europe
Olaparib, Lynparza, Paclitaxel and Carboplatin, Taxol and Paraplatin
Cambridge University Hospitals NHS Foundation Trust, AstraZeneca, Cancer Research UK
Breast Cancer
06/24
06/34
Churn, Mark
POETIC-A, NCT04584853 / 2019-003897-24: PreOperative Endocrine Therapy for Individualised Care With Abemaciclib

Recruiting
3
2032
Europe
Abemaciclib, Verzenios, Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen), Arimidex, Aromasin, Femara, or Tamoxifen
Institute of Cancer Research, United Kingdom
Breast Cancer Female
09/30
03/32
PARTNER, NCT03150576: Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Recruiting
2/3
780
Europe
Olaparib, Lynparza, Paclitaxel and Carboplatin, Taxol and Paraplatin
Cambridge University Hospitals NHS Foundation Trust, AstraZeneca, Cancer Research UK
Breast Cancer
06/24
06/34

Download Options